Get the Stockscreener App
14.68
2.43%
-0.43
Crescent Biopharma Inc stock is traded at $14.68, with a volume of 154.44K.
It is down -2.43% in the last 24 hours and down -19.04% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$15.11
Open:
$14.85
24h Volume:
154.44K
Relative Volume:
0.44
Market Cap:
$404.80M
Revenue:
$11.88M
Net Income/Loss:
$-162.08M
P/E Ratio:
-1.1759
EPS:
-12.484
Net Cash Flow:
$-156.43M
1W Performance:
-14.98%
1M Performance:
-19.04%
6M Performance:
+9.12%
1Y Performance:
+13.23%
1-Day Range:
$14.47
$15.19
1-Week Range:
$14.47
$17.35
52-Week Range:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
14.68 | 416.66M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
484.13 | 123.36B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
672.70 | 71.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
855.05 | 53.68B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
184.25 | 38.09B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
269.30 | 37.80B | 4.29B | 577.22M | 641.34M | 4.2086 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Piper Sandler | Overweight |
| Jan-21-26 | Initiated | Guggenheim | Buy |
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
Crescent Biopharma closes $143.7 million public offering - Investing.com
Crescent Biopharma (CBIO) Proxy filing Summary - Quartr
Crescent Biopharma closes $143.7 million public offering By Investing.com - Investing.com Canada
Crescent Biopharma Offering Closes With 9.4M Shares, Warrants - Stock Titan
Crescent Biopharma (CBIO) Bank of America Global Healthcare Conference 2026 Summary - Quartr
Crescent Bi raises up to $133.5M in registered offering of 8.09M shares and pre-funded warrants - TradingView
Crescent Biopharma (Nasdaq: CBIO) prices $125.0 million stock and warrant sale - Stock Titan
Form 424B5 CRESCENT BIOPHARMA, INC. - StreetInsider
Crescent Biopharma Prices $125 Million Common, Warrant Offering - marketscreener.com
Form 424B5 Crescent Biopharma Inc For: 15 July - Investing.com UK
Crescent Biopharma, Inc. Files 8-K with SEC – Ordinary Shares (CBIO) Listed on NASDAQ, Key Company Details for July 2026 141649 – Minichart - Minichart
Form 424B5 Crescent Biopharma Inc For: 14 July - Investing.com UK
Crescent Biopharma Underwriters Have Option for Nearly 1.3M Additional Shares >CBIO - Moomoo
Crescent Biopharma prices $125M public offering of shares and pre-funded warrants - Pluang
Crescent Biopharma: Jefferies, TD Cowen Among Joint Managers for Offering >CBIO - Moomoo
Crescent Biopharma Also Offering Certain Investors Prefunded Warrants to Buy 525,897 Shares >CBIO - Moomoo
Crescent Biopharma prices $125M public offering at $14.50/share By Investing.com - Investing.com India
Crescent Biopharma Prices $125 Million Public Offering of Ordinary Shares and Pre-Funded Warrants - Quiver Quantitative
Crescent Biopharma Sets $14.50 Price for 8.1M Shares - Stock Titan
Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants - GlobeNewswire
Crescent Biopharma files for underwritten offering of ordinary shares and pre-funded warrants - MSN
Crescent Biopharma prices $125M public offering of shares - scanx.trade
Crescent Biopharma launches public offering of ordinary shares - Investing.com
Crescent Biopharma Launches Offering of Common Shares, Warrants - marketscreener.com
Form 424B5 Crescent Biopharma Inc For: 14 July By Investing.com - Investing.com India
Crescent Biopharma Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants - The Manila Times
Crescent Biopharma launches public offering of ordinary shares By Investing.com - Investing.com UK
Crescent Biopharma (NASDAQ: CBIO) reports $171.6M preliminary cash as of June 30, 2026 - Stock Titan
Crescent Biopharma (NASDAQ: CBIO) details share and pre-funded warrant deal - Stock Titan
Crescent Biopharma Offering Lets Investors Choose Shares or Warrants - Stock Titan
Price to earnings forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
symbol__ Stock Quote Price and Forecast - CNN
[EFFECT] CRESCENT BIOPHARMA, INC. SEC Filing - Stock Titan
Crescent Biopharma Inc (CBIO) - MSN
Crescent Biopharma (CBIO) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
Enterprise value to EBITDA forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
Price to sales forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
Price to earnings forward of Crescent Biopharma, Inc. – FWB:C68 - TradingView
Price to sales forward of Crescent Biopharma, Inc. – FWB:C68 - TradingView
Enterprise value to EBIT forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
ETFs Investing in Crescent Biopharma, Inc. Stocks - TradingView
Crescent Biopharma files prospectus for $500M mixed shelf - scanx.trade
Form S-3 Crescent Biopharma Inc For: 1 July By Investing.com - Investing.com Canada
Crescent BiopharmaMay Offer And Sell Up To $500 Million Of SecuritiesSEC Filing - TradingView
Crescent Biopharma (NASDAQ: CBIO) files $500M shelf; $200M ATM with Jefferies - Stock Titan
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Index - marketscreener.com
Crescent Biopharma Company Profile & Introduction - Moomoo
Crescent Biopharma(CBIO) Stock Options Chain | Quotes & News - Moomoo
Crescent Biopharma: Intriguing Developer Of ADC/PD1-VEGF Assets May Not Be Sufficiently Derisked - Seeking Alpha
Crescent Biopharma, Inc.(NasdaqCM:CBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):